Evidence map›Paper›PMID 42198783›Full record

ArticleViruses2026

Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses.

Shuai Shang, Qikai Yin, Tingyi Che, Xinzhu Wang, Qi Su, Shihong Fu, Hongshan Xu, Yongxin Yu, Qunying Mao, Huanyu Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuai ShangNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Qikai YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.ORCID 0000-0001-8239-0214
Tingyi CheNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Xinzhu WangNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Qi SuNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Shihong FuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Hongshan XuNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Yongxin YuNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Qunying MaoNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Huanyu WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.ORCID 0000-0001-6245-2027
Xinyu LiuNational Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.

Funding

Beijing City Natural Science Foundation Project No. L252074.
6 · The paper itself

Abstract

Japanese encephalitis virus (JEV) comprises a single serotype but can be classified into five genotypes (genotypes I-V, GI-GV) based on nucleic acid sequences. Historically, genotype III (GIII) was the predominant strain. However, since the 21st century, genotype I (GI) rapidly replaced GIII as the major genotype in China, Southeast Asia, and other regions. The live attenuated vaccine (LAV) SA14-14-2, licensed in China in 1988, was successfully exported to 13 countries, with cumulative vaccinations exceeding one billion doses. The vaccine seed virus SA14-14-2 belonged to genotype III. Whether this GIII-based vaccine provided sufficient protection against the currently circulating GI strains warranted systematic investigation. In this study, recent JEV isolates collected from China were subjected to genotypic analysis, followed by comprehensive evaluations including protective efficacy against challenge and serum neutralizing antibody levels. The results indicated that, despite antigenic differences between GIII and GI strains, no significant differences in protective efficacy post-challenge were observed. The SA14-14-2 LAV remained effective in preventing GI strain infection.

Indexed as

Antibodies, NeutralizingAntibodies, ViralEncephalitis Virus, JapaneseJapanese Encephalitis VaccinesAnimalsAnimals, Outbred StrainsChinaFemaleGenotypeMaleMiceVaccine EfficacyVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralJapanese Encephalitis VaccinesSA-14-14-2 vaccineVaccines, Attenuatedcross-protectiongenotype I (GI)genotype III (GIII)genotype shiftJapanese encephalitis virus (JEV)live attenuated vaccine (LAV)neutralizing antibodiesSA14-14-2 vaccine

Identifiers

PMID42198783
PMCPMC13211682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.